Astrazeneca Plc (AZN) 73.35 $AZN
Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:11AM CDT
Biotechnology is rapidly giving rise to ground-breaking new medicines that are dramatically changing the outlook for devastating diseases such as hepatitis C, malaria, and, perhaps most astoundingly, cancer. This innovation boom has gone hand in hand...
AGEN: 6.08 (+0.21), ADXS: 22.18 (+0.10), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), BMY: 66.60 (-0.21), FPRX: 24.07 (-0.85)
Novavax Is Our Favorite Idea That Everyone Knows, But That No One Understands
Clinically Sound Investor - at Seeking Alpha - Tue Apr 21, 10:04AM CDT
NVAX: 8.51 (+0.09), AZN: 73.35 (+0.65), NLNK: 53.12 (-0.07)
Bina Technologies and AstraZeneca Announce Collaborative Agreement for Global Deployment of Bina's Genomic Management Solution
Business Wire - Tue Apr 21, 6:00AM CDT
Bina Technologies, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AstraZeneca (NYSE: AZN) today announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Program and to further develop the Bina Genomic Management Solution (GMS)(1). AstraZeneca will utilize the Bina GMS as an enterprise platform to support its development work across three main therapeutic areas: oncology, cardiovascular and metabolic disease, and respiratory, inflammation and autoimmunity.
AZN: 73.35 (+0.65)
Athersys Slumps as MultiStem Fails in Mid-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 5:14PM CDT
Athersys (ATHX) announced disappointing interim results from a phase II study on MultiStem cell therapy.
BIIB: 423.57 (+1.46), AZN: 73.35 (+0.65), AVEO: 2.04 (+0.12), ATHX: 1.34 (+0.01)
Is Bristol-Myers Squibb. Co. About to Fall Apart?
George Budwell, The Motley Fool - Motley Fool - Mon Apr 20, 7:08AM CDT
Big pharma has been having a rough go of it since the patent cliff kicked into high gear in 2012. But you wouldn't be able to tell it by how shares of the pharma giant Bristol-Myers Squibb have been trading. Specifically, Bristol's shares have...
MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), BMY: 66.60 (-0.21)
3 Top Healthcare Stocks Surging Higher This Year
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 18, 11:03AM CDT
Aging baby boomers and an increasingly insured population are driving healthcare utilization higher, and that has made stocks in this industry some of the market's best performers over the past three years. A number of healthcare stocks are soaring...
ESPR: 100.53 (-2.60), AZN: 73.35 (+0.65), HZNP: 30.96 (+0.10), TEVA: 63.01 (-1.15), EGRX: 60.53 (+1.22), HPTX: 45.96 (-0.18)
Seeking Alpha's Biotech Weekly: Celgene Check-Up, Is Gilead The New Apple?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors geared up for earnings season, highlighted several...
SGYP: 4.01 (-0.06), BIIB: 423.57 (+1.46), ARWR: 6.88 (+0.14), AMGN: 169.10 (+0.64), MYL: 72.40 (-1.67), BMY: 66.60 (-0.21), CNCE: 14.83 (+0.26), CELG: 115.54 (+0.72), ATNM: 3.01 (-0.07), PFS: 18.65 (+0.06), NVIV: 13.76 (-0.19), GILD: 104.18 (-1.02), FWP: 31.77 (-0.66), GWPH: 113.04 (-0.05), IBM: 165.36 (+1.10), BAX: 70.38 (+0.33), AZN: 73.35 (+0.65), TEVA: 63.01 (-1.15)
"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC
PR Newswire Europe - Fri Apr 17, 9:31AM CDT
GENEVA, April 17, 2015 /PRNewswire/ --
AZN: 73.35 (+0.65)
Buy These 4 High-Yield Dividend Stocks to Take Advantage of the Health Care Boom
at The Street - Fri Apr 17, 7:51AM CDT
Health care stocks are up 33% over the last 12 months, nearly doubling the return of the S&P 500.
VIVO: 18.89 (+0.01), GEN: 7.28 (+0.08), AZN: 73.35 (+0.65), GSK: 46.57 (-0.67), XLV: 74.35 (+0.12)
AstraZeneca experimental cancer drug extends PFS in treatment-resistant form of lung cancer
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 6:58AM CDT
AZN: 73.35 (+0.65)
AstraZeneca's selumetinib an Orphan Drug for eye cancer
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 6:09AM CDT
AZN: 73.35 (+0.65)
AstraZeneca's Onglyza Label Needs Revision per FDA Panel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 5:04PM CDT
AstraZeneca's (AZN) Onglyza and Kombiglyze XR labels have been recommended to include new safety information as per an FDA panel.
MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), AVEO: 2.04 (+0.12), LLY: 72.30 (+0.09)
Pfizer's Ibrance Study Stopped Early on Favorable Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 4:00PM CDT
Pfizer announced that based on an assessment by an independent Data Monitoring Committee, a phase III study on Ibrance was stopped early as the study met its primary endpoint.
VRX: 206.93 (-3.92), PFE: 34.93 (+0.04), AZN: 73.35 (+0.65), NVS: 103.45 (-0.62)
4 Big Biopharma Deals We Might See In 2015
Sy Mukherjee - Seeking Alpha - Thu Apr 16, 1:29PM CDT
In 2000, UK-based Glaxo Wellcome joined forces with SmithKline Beecham in a $74 billion merger that birthed the global pharma giant GlaxoSmithKline (NYSE: GSK ). It was, far and away, the biggest biopharma deal of the year. What a difference 14...
BMRN: 121.08 (-0.16), PCYC: 256.98 (-0.77), PFE: 34.93 (+0.04), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), HSP: 87.80 (+0.04), CELG: 115.54 (+0.72), SGEN: 36.92 (-0.32), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), AZN: 73.35 (+0.65), JAZZ: 186.13 (-0.41), MRK: 57.69 (+0.03), ABBV: 64.52 (+0.91)
Global Influenza Vaccine Market Outlook 2020
M2 - Thu Apr 16, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l9hk3c/global_influenza) has announced the addition of the "Global Influenza Vaccine Market Outlook 2020" report to their offering. The global volume sales of influenza vaccine is expected to grow at a CAGR of 5.5% during the forecasted period, 2014-2020 Influenza vaccines are considered as an optimum source of prevention from diseases caused by flu virus. Since the H1N1 pandemic, worldwide authorities have started to adopt proactive approach in the vaccination process. Virus of previous pandemics are still circulating in the environment and in the coming future, they may be classified as strains to be updated in seasonal vaccines. Moreover, a large chunk of global population is affected by influenza-related problems. In such a scenario, huge opportunity lies for industry participants to tap the fast growing market. In 2014, the global market for influenza vaccines has shown tremendous growth backed by certain key prominent factors. Approval of new seasonal influenza vaccines by authorities and significant developments in adjuvant technology are going to impact the market in a positive manner. . Emerging markets predominantly is the main focus in the global influenza vaccine market landscape. Vast population base together with significantly low vaccination coverage are the prominent factors that will drive the future growth in countries, such as China and India. Market players have already started devising strategies including agreements with domestic manufacturers/distributors to increase their presence in China. India, on the contrary, is engaged in the collection of data that may facilitate in the development of flu vaccination strategies among the population. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Influenza Vaccine - Introduction 4. Global Influenza Vaccine Market Outlook 2020 5. Key Geographical Market 6. Global Influenza Vaccine Market: Pipeline Analysis 7. Global Influenza Vaccine Market: Pricing Analysis 8. Competitive Assessment - Sanofi - GlaxoSmithKline Plc (GSK) - CSL Ltd - AstraZeneca Plc - Sinovac Biotech - Serum Institute of India For more information visit http://www.researchandmarkets.com/research/l9..._influenza
AZN: 73.35 (+0.65), GSK: 46.57 (-0.67), SVA: 5.06 (+0.10)
Pfizer, Biogen, AbbVie Get Good Drug-Trial News
at Investor's Business Daily - Wed Apr 15, 10:49AM CDT
Good clinical-trial news rolled in for leading drugmakers Wednesday, helping to buoy the group's recovery on the stock market. Big pharma Pfizer (PFE) said early Wednesday that it had stopped a phase-three trial of its drug Ibrance early because it...
BIIB: 423.57 (+1.46), AZN: 73.35 (+0.65), PFE: 34.93 (+0.04), ABBV: 64.52 (+0.91), NVS: 103.45 (-0.62)
Big Pharmas' Dirty Little Secret About Cholesterol Lowering Drugs
Mark Chapman - at Seeking Alpha - Wed Apr 15, 10:19AM CDT
ESPR: 100.53 (-2.60), ALNY: 118.00 (-2.70), MDCO: 27.84 (+0.25), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41)
AstraZeneca's tremelimumab an Orphan Drug for mesothelioma
Seeking Alpha - at Seeking Alpha - Wed Apr 15, 8:57AM CDT
AZN: 73.35 (+0.65)
Equities Updates on Pharma Industry -- Eli Lilly, Sanofi, AstraZeneca, Nektar Therapeutics, and BioDelivery Sciences Intl.
PR Newswire - Wed Apr 15, 8:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BDSI: 9.26 (+0.12), AZN: 73.35 (+0.65), LLY: 72.30 (+0.09), SNY: 51.59 (+0.03), NKTR: 10.90 (+0.16)
Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:11AM CDT
Biotechnology is rapidly giving rise to ground-breaking new medicines that are dramatically changing the outlook for devastating diseases such as hepatitis C, malaria, and, perhaps most astoundingly, cancer. This innovation boom has gone hand in hand...
AGEN: 6.08 (+0.21), ADXS: 22.18 (+0.10), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), BMY: 66.60 (-0.21), FPRX: 24.07 (-0.85)
Novavax Is Our Favorite Idea That Everyone Knows, But That No One Understands
Clinically Sound Investor - at Seeking Alpha - Tue Apr 21, 10:04AM CDT
NVAX: 8.51 (+0.09), AZN: 73.35 (+0.65), NLNK: 53.12 (-0.07)
Bina Technologies and AstraZeneca Announce Collaborative Agreement for Global Deployment of Bina's Genomic Management Solution
Business Wire - Tue Apr 21, 6:00AM CDT
Bina Technologies, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AstraZeneca (NYSE: AZN) today announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Program and to further develop the Bina Genomic Management Solution (GMS)(1). AstraZeneca will utilize the Bina GMS as an enterprise platform to support its development work across three main therapeutic areas: oncology, cardiovascular and metabolic disease, and respiratory, inflammation and autoimmunity.
AZN: 73.35 (+0.65)
Athersys Slumps as MultiStem Fails in Mid-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 5:14PM CDT
Athersys (ATHX) announced disappointing interim results from a phase II study on MultiStem cell therapy.
BIIB: 423.57 (+1.46), AZN: 73.35 (+0.65), AVEO: 2.04 (+0.12), ATHX: 1.34 (+0.01)
Is Bristol-Myers Squibb. Co. About to Fall Apart?
George Budwell, The Motley Fool - Motley Fool - Mon Apr 20, 7:08AM CDT
Big pharma has been having a rough go of it since the patent cliff kicked into high gear in 2012. But you wouldn't be able to tell it by how shares of the pharma giant Bristol-Myers Squibb have been trading. Specifically, Bristol's shares have...
MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), BMY: 66.60 (-0.21)
3 Top Healthcare Stocks Surging Higher This Year
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 18, 11:03AM CDT
Aging baby boomers and an increasingly insured population are driving healthcare utilization higher, and that has made stocks in this industry some of the market's best performers over the past three years. A number of healthcare stocks are soaring...
ESPR: 100.53 (-2.60), AZN: 73.35 (+0.65), HZNP: 30.96 (+0.10), TEVA: 63.01 (-1.15), EGRX: 60.53 (+1.22), HPTX: 45.96 (-0.18)
Seeking Alpha's Biotech Weekly: Celgene Check-Up, Is Gilead The New Apple?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors geared up for earnings season, highlighted several...
SGYP: 4.01 (-0.06), BIIB: 423.57 (+1.46), ARWR: 6.88 (+0.14), AMGN: 169.10 (+0.64), MYL: 72.40 (-1.67), BMY: 66.60 (-0.21), CNCE: 14.83 (+0.26), CELG: 115.54 (+0.72), ATNM: 3.01 (-0.07), PFS: 18.65 (+0.06), NVIV: 13.76 (-0.19), GILD: 104.18 (-1.02), FWP: 31.77 (-0.66), GWPH: 113.04 (-0.05), IBM: 165.36 (+1.10), BAX: 70.38 (+0.33), AZN: 73.35 (+0.65), TEVA: 63.01 (-1.15)
"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC
PR Newswire Europe - Fri Apr 17, 9:31AM CDT
GENEVA, April 17, 2015 /PRNewswire/ --
AZN: 73.35 (+0.65)
Buy These 4 High-Yield Dividend Stocks to Take Advantage of the Health Care Boom
at The Street - Fri Apr 17, 7:51AM CDT
Health care stocks are up 33% over the last 12 months, nearly doubling the return of the S&P 500.
VIVO: 18.89 (+0.01), GEN: 7.28 (+0.08), AZN: 73.35 (+0.65), GSK: 46.57 (-0.67), XLV: 74.35 (+0.12)
AstraZeneca experimental cancer drug extends PFS in treatment-resistant form of lung cancer
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 6:58AM CDT
AZN: 73.35 (+0.65)
AstraZeneca's selumetinib an Orphan Drug for eye cancer
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 6:09AM CDT
AZN: 73.35 (+0.65)
AstraZeneca's Onglyza Label Needs Revision per FDA Panel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 5:04PM CDT
AstraZeneca's (AZN) Onglyza and Kombiglyze XR labels have been recommended to include new safety information as per an FDA panel.
MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), AVEO: 2.04 (+0.12), LLY: 72.30 (+0.09)
Pfizer's Ibrance Study Stopped Early on Favorable Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 4:00PM CDT
Pfizer announced that based on an assessment by an independent Data Monitoring Committee, a phase III study on Ibrance was stopped early as the study met its primary endpoint.
VRX: 206.93 (-3.92), PFE: 34.93 (+0.04), AZN: 73.35 (+0.65), NVS: 103.45 (-0.62)
4 Big Biopharma Deals We Might See In 2015
Sy Mukherjee - Seeking Alpha - Thu Apr 16, 1:29PM CDT
In 2000, UK-based Glaxo Wellcome joined forces with SmithKline Beecham in a $74 billion merger that birthed the global pharma giant GlaxoSmithKline (NYSE: GSK ). It was, far and away, the biggest biopharma deal of the year. What a difference 14...
BMRN: 121.08 (-0.16), PCYC: 256.98 (-0.77), PFE: 34.93 (+0.04), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), HSP: 87.80 (+0.04), CELG: 115.54 (+0.72), SGEN: 36.92 (-0.32), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), AZN: 73.35 (+0.65), JAZZ: 186.13 (-0.41), MRK: 57.69 (+0.03), ABBV: 64.52 (+0.91)
Global Influenza Vaccine Market Outlook 2020
M2 - Thu Apr 16, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l9hk3c/global_influenza) has announced the addition of the "Global Influenza Vaccine Market Outlook 2020" report to their offering. The global volume sales of influenza vaccine is expected to grow at a CAGR of 5.5% during the forecasted period, 2014-2020 Influenza vaccines are considered as an optimum source of prevention from diseases caused by flu virus. Since the H1N1 pandemic, worldwide authorities have started to adopt proactive approach in the vaccination process. Virus of previous pandemics are still circulating in the environment and in the coming future, they may be classified as strains to be updated in seasonal vaccines. Moreover, a large chunk of global population is affected by influenza-related problems. In such a scenario, huge opportunity lies for industry participants to tap the fast growing market. In 2014, the global market for influenza vaccines has shown tremendous growth backed by certain key prominent factors. Approval of new seasonal influenza vaccines by authorities and significant developments in adjuvant technology are going to impact the market in a positive manner. . Emerging markets predominantly is the main focus in the global influenza vaccine market landscape. Vast population base together with significantly low vaccination coverage are the prominent factors that will drive the future growth in countries, such as China and India. Market players have already started devising strategies including agreements with domestic manufacturers/distributors to increase their presence in China. India, on the contrary, is engaged in the collection of data that may facilitate in the development of flu vaccination strategies among the population. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Influenza Vaccine - Introduction 4. Global Influenza Vaccine Market Outlook 2020 5. Key Geographical Market 6. Global Influenza Vaccine Market: Pipeline Analysis 7. Global Influenza Vaccine Market: Pricing Analysis 8. Competitive Assessment - Sanofi - GlaxoSmithKline Plc (GSK) - CSL Ltd - AstraZeneca Plc - Sinovac Biotech - Serum Institute of India For more information visit http://www.researchandmarkets.com/research/l9..._influenza
AZN: 73.35 (+0.65), GSK: 46.57 (-0.67), SVA: 5.06 (+0.10)
Pfizer, Biogen, AbbVie Get Good Drug-Trial News
at Investor's Business Daily - Wed Apr 15, 10:49AM CDT
Good clinical-trial news rolled in for leading drugmakers Wednesday, helping to buoy the group's recovery on the stock market. Big pharma Pfizer (PFE) said early Wednesday that it had stopped a phase-three trial of its drug Ibrance early because it...
BIIB: 423.57 (+1.46), AZN: 73.35 (+0.65), PFE: 34.93 (+0.04), ABBV: 64.52 (+0.91), NVS: 103.45 (-0.62)
Big Pharmas' Dirty Little Secret About Cholesterol Lowering Drugs
Mark Chapman - at Seeking Alpha - Wed Apr 15, 10:19AM CDT
ESPR: 100.53 (-2.60), ALNY: 118.00 (-2.70), MDCO: 27.84 (+0.25), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41)
AstraZeneca's tremelimumab an Orphan Drug for mesothelioma
Seeking Alpha - at Seeking Alpha - Wed Apr 15, 8:57AM CDT
AZN: 73.35 (+0.65)
Equities Updates on Pharma Industry -- Eli Lilly, Sanofi, AstraZeneca, Nektar Therapeutics, and BioDelivery Sciences Intl.
PR Newswire - Wed Apr 15, 8:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BDSI: 9.26 (+0.12), AZN: 73.35 (+0.65), LLY: 72.30 (+0.09), SNY: 51.59 (+0.03), NKTR: 10.90 (+0.16)
